Clinical Advances in Cancer Immunotherapy

Submission Deadline: October 31, 2025

Guest Editor:

Dr. Zhe Wang
The First Affiliated Hospital of Zhengzhou University

Co-Guest Editors:

Dao Xin
The First Affiliated Hospital of Zhengzhou University

Feng Wang
The First Affiliated Hospital of Zhengzhou University

Special Issue Information:

Dear Colleagues,

In recent years, cancer immunotherapy has transformed the treatment landscape for a variety of malignancies. However, significant challenges remain in optimizing treatment strategies, predicting patient response, overcoming resistance mechanisms, and integrating immunotherapy into multimodal regimens.

This special issue aims to provide a comprehensive update on recent clinical advances in cancer immunotherapy, including but not limited to:

Biomarker discovery and predictive tools for immunotherapy response
Clinical trials involving checkpoint inhibitors, bispecific antibodies, and cancer vaccines
Combination therapies, such as immunotherapy plus chemotherapy, radiotherapy, or targeted therapy
Mechanisms of resistance and novel strategies to overcome them
Real-world evidence and translational insights from bench to bedside
Immunotherapy in special populations, including elderly patients and those with rare cancers

We welcome high-quality original research articles, clinical studies, and in-depth reviews that explore the current landscape and future directions of cancer immunotherapy from a clinical perspective. For planned papers, a title and short abstract can be sent to the Editorial Office cindy@ukscip.com for announcement on this website.

Guest Editor(s)
Dr. Zhe Wang
Dao Xin
Feng Wang

Keywords:

Immunotherapy
Cancer, Biomarkers
Immune Checkpoint Inhibitors
Resistance Mechanisms
Combination Therapy
Clinical Trials, Translational Oncology
Tumor Microenvironment, Real-World Evidence